<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurotox Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurotox Res</journal-id>
<journal-title-group>
<journal-title>Neurotoxicity Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">1029-8428</issn>
<issn pub-type="epub">1476-3524</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28247204</article-id>
<article-id pub-id-type="pmc">5360820</article-id>
<article-id pub-id-type="publisher-id">9708</article-id>
<article-id pub-id-type="doi">10.1007/s12640-017-9708-y</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Changes in the Brain Endocannabinoid System in Rat Models of Depression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Smaga</surname>
<given-names>Irena</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jastrzębska</surname>
<given-names>Joanna</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zaniewska</surname>
<given-names>Magdalena</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bystrowska</surname>
<given-names>Beata</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gawliński</surname>
<given-names>Dawid</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faron-Górecka</surname>
<given-names>Agata</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Broniowska</surname>
<given-names>Żaneta</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miszkiel</surname>
<given-names>Joanna</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Filip</surname>
<given-names>Małgorzata</given-names>
</name>
<address>
<phone>+48 12 6623293</phone>
<email>mal.fil@if-pan.krakow.pl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2162 9631</institution-id><institution-id institution-id-type="GRID">grid.5522.0</institution-id><institution>Department of Toxicology, Faculty of Pharmacy, College of Medicum, </institution><institution>Jagiellonian University, </institution></institution-wrap>Medyczna 9, PL 30-688 Kraków, Poland </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1958 0162</institution-id><institution-id institution-id-type="GRID">grid.413454.3</institution-id><institution>Laboratory of Drug Addiction Pharmacology, Institute of Pharmacology, </institution><institution>Polish Academy of Sciences, </institution></institution-wrap>Smętna 12, PL 31-343 Kraków, Poland </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1958 0162</institution-id><institution-id institution-id-type="GRID">grid.413454.3</institution-id><institution>Laboratory of Biochemical Pharmacology, Institute of Pharmacology, </institution><institution>Polish Academy of Sciences, </institution></institution-wrap>Smętna 12, PL 31-343 Kraków, Poland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>28</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2017</year>
</pub-date>
<volume>31</volume>
<issue>3</issue>
<fpage>421</fpage>
<lpage>435</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>8</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>2</day>
<month>2</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>2</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>A growing body of evidence implicates the endocannabinoid (eCB) system in the pathophysiology of depression. The aim of this study was to investigate the influence of changes in the eCB system, such as levels of neuromodulators, eCB synthesizing and degrading enzymes, and cannabinoid (CB) receptors, in different brain structures in animal models of depression using behavioral and biochemical analyses. Both models used, i.e., bulbectomized (OBX) and Wistar Kyoto (WKY) rats, were characterized at the behavioral level by increased immobility time. In the OBX rats, anandamide (AEA) levels were decreased in the prefrontal cortex, hippocampus, and striatum and increased in the nucleus accumbens, while 2-arachidonoylglycerol (2-AG) levels were increased in the prefrontal cortex and decreased in the nucleus accumbens with parallel changes in the expression of eCB metabolizing enzymes in several structures. It was also observed that CB<sub>1</sub> receptor expression decreased in the hippocampus, dorsal striatum, and nucleus accumbens, and CB<sub>2</sub> receptor expression decreased in the prefrontal cortex and hippocampus. In WKY rats, the levels of eCBs were reduced in the prefrontal cortex (2-AG) and dorsal striatum (AEA) and increased in the prefrontal cortex (AEA) with different changes in the expression of eCB metabolizing enzymes, while the CB<sub>1</sub> receptor density was increased in several brain regions. These findings suggest that dysregulation in the eCB system is implicated in the pathogenesis of depression, although neurochemical changes were linked to the particular brain structure and the factor inducing depression (surgical removal of the olfactory bulbs vs. genetic modulation).</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Animal model of depression</kwd>
<kwd>Endocannabinoid system</kwd>
<kwd>Olfactory bulbectomy</kwd>
<kwd>Wistar Kyoto</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution>National Science Centre, Kraków, Poland </institution>
</funding-source>
<award-id>UMO-2012/05/B/NZ7/02589</award-id>
</award-group>
<award-group>
<funding-source>
<institution>the statutory funds from the Jagiellonian University</institution>
</funding-source>
<award-id>K/DSC/001425</award-id>
<principal-award-recipient>
<name>
<surname>Smaga</surname>
<given-names>Irena</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group>
<funding-source>
<institution>the statutory funds of the Institute of Pharmacology of the Polish Academy of Sciences</institution>
</funding-source>
</award-group>
<award-group>
<funding-source>
<institution>"Doctus- Malopolska scholarship program for doctoral students" </institution>
</funding-source>
<award-id>ZS.4112-51/12</award-id>
<principal-award-recipient>
<name>
<surname>Smaga</surname>
<given-names>Irena</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media New York 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p>At present, depression is one of the most common psychiatric disorders, but its pharmacotherapy and pathophysiology are still unclear. The etiology of depression is multifactorial and related to disturbed monoaminergic transmission, changes in receptor function, dysregulation of the stress axis, a reduction of neurogenesis, activated inflammatory processes, or increased oxidative stress (Moniczewski et al. <xref ref-type="bibr" rid="CR54">2015</xref>; Smaga et al. <xref ref-type="bibr" rid="CR73">2015</xref>). Recent observations strongly support the involvement of the endocannabinoid (eCB) system in the pathogenesis of depression. In preclinical studies, genetic deletion of the cannabinoid (CB<sub>1</sub>) receptor or the CB<sub>1</sub> receptor blockade resulted in depressive-like behavior (Sanchis-Segura et al. <xref ref-type="bibr" rid="CR67">2004</xref>; Aso et al. <xref ref-type="bibr" rid="CR7">2008</xref>; Steiner et al. <xref ref-type="bibr" rid="CR77">2008</xref>; Mikics et al. <xref ref-type="bibr" rid="CR53">2009</xref>). On the other hand, the facilitation of eCB signaling exerts antidepressant-like behavioral responses in rodents, which were observed after: anandamide (AEA) administration (Umathe et al. <xref ref-type="bibr" rid="CR79">2011</xref>), AEA uptake inhibition (Hill and Gorzalka <xref ref-type="bibr" rid="CR25">2005</xref>; Adamczyk et al. <xref ref-type="bibr" rid="CR2">2008</xref>; Mannucci et al. <xref ref-type="bibr" rid="CR48">2011</xref>; Umathe et al. <xref ref-type="bibr" rid="CR79">2011</xref>), eCB degrading enzyme inhibition (Gobbi et al. <xref ref-type="bibr" rid="CR23">2005</xref>; Adamczyk et al. <xref ref-type="bibr" rid="CR2">2008</xref>), or by direct CB<sub>1</sub> agonists (Bambico et al. <xref ref-type="bibr" rid="CR8">2007</xref>; Haring et al. <xref ref-type="bibr" rid="CR24">2013</xref>; Smaga et al. <xref ref-type="bibr" rid="CR72">2014b</xref>). Moreover, reduction of eCB signaling was linked to depressive-like behavior in several models of depression (Hill et al. <xref ref-type="bibr" rid="CR26">2005</xref>, <xref ref-type="bibr" rid="CR28">2008a</xref>; Eisenstein et al. <xref ref-type="bibr" rid="CR21">2010</xref>; Dubreucq et al. <xref ref-type="bibr" rid="CR20">2012</xref>; Vinod et al. <xref ref-type="bibr" rid="CR82">2012</xref>). In a human study, administration of a CB<sub>1</sub> antagonist (rimonabant) (Christensen et al. <xref ref-type="bibr" rid="CR16">2007</xref>; Horder et al. <xref ref-type="bibr" rid="CR33">2009</xref>) for treatment of obesity resulted in the development of depression and anhedonia. Additionally, augmentation of eCB signaling evoked different changes implicated in antidepressant effects, such as modulation of neurotransmitter release, regulation of the stress axis, promotion of neurogenesis, and normalization of the excitation state (Smaga et al. <xref ref-type="bibr" rid="CR71">2014a</xref>, <xref ref-type="bibr" rid="CR72">b</xref>).</p>
<p>The aim of the present study was to perform a complex analysis to the eCB system (i.e., endogenous ligands, enzymes involved in eCB metabolism, and CB receptors) in the pathogenesis of depression by using valid animal models of depression: Wistar Kyoto (WKY) rats and bulbectomized (OBX) animals. We focused on determining whether the levels of eCBs (i.e., AEA and 2-arachidonoylglycerol (2-AG)), the expression of the eCB synthesizing enzymes (N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) and diacylglycerol lipase α (DAGLα)), or eCB degrading enzymes (fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) were altered in particular models of depression. Finally, we measured the expression of CB receptors and CB<sub>1</sub> receptor density. The olfactory bulbectomy is used as a model of depression induced by an injury and is characterized by all of the proper criteria of validity (face, construct, and predictive) that demonstrate a good clinical picture of depression (Abelaira et al. <xref ref-type="bibr" rid="CR1">2013</xref>). On the other hand, WKY rats are an example of a genetic model of depression and are characterized by hyperactive responses to stress with dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis. Both of these models demonstrated behavioral, biochemical, and physiological abnormalities reminiscent of depressive-like symptom (Will et al. <xref ref-type="bibr" rid="CR84">2003</xref>; Yuan and Slotnick <xref ref-type="bibr" rid="CR87">2014</xref>).</p>
</sec>
<sec id="Sec2">
<title>Experimental Procedures</title>
<sec id="Sec3">
<title>Animals</title>
<p>The experiments were performed on male Wistar and WKY rats (Charles River, Germany) weighing 280–300 g (approximately 8–9 weeks old). The animals were kept on a normal day-night cycle at 22 ± 2 °C with access to food and water ad libitum. All experiments were carried out in accordance with the EU directive 2010/63/EU and with approval of the Bioethics Commission as compliant with the Polish Law (21 August 1997). There were 6–8 animals per group.</p>
<sec id="Sec4">
<title>Olfactory Bulbectomy</title>
<p>During anesthesia (ketamine hydrochloride and xylazine mixture in 3:1 <italic>v</italic>/<italic>v</italic>, im), bilateral olfactory bulbectomy was performed on Wistar rats. Metoxicam (0.05 mg/kg, sc) was given as an analgesic and anti-inflammatory drug 60 min before the surgery and for 2 days after the surgery. Two burr holes were drilled on either side of the skull (taking care not to damage the prefrontal cortex), 2 mm in diameter, 8 mm anterior to the bregma, and 2 mm from the midline of the frontal bone overlying the olfactory bulbs (coordinates were taken from the Rat Brain Atlas, Paxinos and Watson <xref ref-type="bibr" rid="CR59">1998</xref>). The olfactory bulbs were removed by suction, and the burr holes were filled with a hemostatic sponge to control bleeding. The skin was closed. Animals receiving sham (SHAM) surgery underwent a similar procedure but did not have their olfactory bulbs removed. During the 14-day recovery, the animals were handled daily by the experimenter to eliminate any aggressiveness that would otherwise develop (Leonard and Tuite <xref ref-type="bibr" rid="CR44">1981</xref>; Smaga et al. <xref ref-type="bibr" rid="CR70">2012</xref>). After the behavioral procedures, the OBX rats were sacrificed through decapitation, and their brains were rapidly removed and examined for signs of cortical damage or incomplete removal of the olfactory bulbs. Such animals were excluded from the data analysis.</p>
</sec>
</sec>
<sec id="Sec5">
<title>Behavioral Tests</title>
<sec id="Sec6">
<title>Locomotor Activity</title>
<p>Open field locomotor activity was recorded individually for each animal in Opto-Varimex cages (Columbus Instruments, Columbus, OH, USA) linked on-line to a compatible IBM PC. Each cage (43 × 44 cm) was equipped with 15 infrared emitters located on the <italic>x</italic> and <italic>y</italic> axes, 3 cm from the floor and with the same number of receivers on the opposite walls of the cage. The rats’ behavior was analyzed using Auto-Track software (Columbus Instruments, Columbus, OH, USA). Locomotor activity was defined as a breakage of three consecutive photobeams. Locomotor activity was defined as horizontal activity and presented as distance traveled in centimeter during 30-min trial (with 5-min intervals).</p>
</sec>
<sec id="Sec7">
<title>Forced Swimming Test (FST)</title>
<p>On the first day of the forced swim (i.e., pre-test), the rats were placed individually in a cylinder (50 cm high × 23 cm in diameter) filled to a 30-cm depth with water (25 ± 1 °C) for 15 min; they were then removed from the water, dried with towels, placed in a warmer enclosure for 15 min, and were then returned to their home cages, as described previously (Frankowska et al. <xref ref-type="bibr" rid="CR22">2010</xref>). The cylinders were emptied and cleaned between rats. Twenty-four hours following the first exposure, the rats were tested for 5 min (300 s) under identical conditions. Test sessions were scored by two observers unaware of the treatment condition, and the immobility time was measured. A rat was considered to be immobile if it was only making movements necessary to keep its head above water.</p>
</sec>
</sec>
<sec id="Sec8">
<title>Tissue Isolation</title>
<p>For biochemical analysis, experimental-naïve rats (WKY, OBX, and corresponding controls) were sacrificed through decapitation, and their brains were rapidly removed. Selected brain structures (i.e., the prefrontal cortex, frontal cortex, hippocampus, dorsal striatum, nucleus accumbens, and cerebellum) were isolated using brain matrix according to The Rat Brain Atlas (Paxinos and Watson <xref ref-type="bibr" rid="CR59">1998</xref>), immediately frozen on dry ice and stored at −80 °C for liquid chromatography tandem mass spectrometry (LC-MS/MS) and Western blot analysis. Separate groups of animals were used for autoradiography; their brains were rapidly dissected, frozen by dry-ice bath using heptane, and were later stored at −80 °C until sectioned.</p>
</sec>
<sec id="Sec9">
<title>Biochemical Analysis</title>
<sec id="Sec10">
<title>LC-MS/MS</title>
<sec id="FPar1">
<title>Reagents</title>
<p>All chemical solvents and standards were of analytical grade. Standards of AEA and 2-AG were obtained from Tocris (Bristol, United Kingdom), AEA-d<sub>4</sub> and 2-AG-d<sub>5</sub> from Cayman Chemical (USA), acetonitrile and chloroform from Merck (Darmstadt, Germany), and methanol and formic acid from POCh (Katowice, Poland). Standard stock solutions were prepared in ethanol (AEA and AEA-d<sub>4</sub>) or acetonitrile (2-AG and 2-AG-d<sub>5</sub>). All stock solutions were stored at −80 °C. Further dilutions were carried out appropriately in acetonitrile.</p>
</sec>
<sec id="FPar2">
<title>Lipid Extraction from Brain Tissue</title>
<p>The brain tissues were weighed and subjected to eCB extraction. Extraction was carried out by the modified methods of isolation of lipid compounds, as described previously (Bystrowska et al. <xref ref-type="bibr" rid="CR14">2014b</xref>). Tissues were homogenized using a sonicator (UP50H, Hielscher) in the ice-cold mixture of methanol and chloroform (1:2, <italic>v</italic>/<italic>v</italic>) in the proportion of 10 mg of wet tissue to 150 μl of solvent to quench any possible enzymatic reaction that may interfere with the analysis. Next, 150 μl of homogenate were mixed with 2 μl of internal standard (AEA-d<sub>4</sub>, concentration 10 μg/ml; 2-AG-d<sub>5</sub>, concentration 100 μg/ml), 250 μl of formic acid (pH 3.0; 0.2 M), and 1500 μl of extraction mixture (methanol:chloroform 1:2, <italic>v</italic>/<italic>v</italic>). The internal standard indicates analyte loss during sample work-up. Afterward, samples were vortexed for 30 s and centrifuged for 10 min at 2000 rpm. Organic phases were collected and dried under a stream of nitrogen at 40 °C. The residue was dissolved in 40 μl of acetonitrile, and 10 μl of the reconstituted extract was injected into the LC-MS/MS system for quantitative analysis.</p>
</sec>
<sec id="FPar3">
<title>LC-MS/MS Conditions</title>
<p>LC was performed using an Agilent 1100 (Agilent Technologies, Waldbronn, Germany) LC system. Chromatographic separation was carried out with a Thermo Scientific BDS HYPERSIL C18 column (100 × 3 mm I.D., 3-μm particle size). The advance column with precolumn (10 × 3 mm I.D., 3-μm particle size) was set at 40 °C with a mobile phase flow rate of 0.3 ml/min. Gradient elution mobile phases consisted of formic acid (0.02 M) in water (solvent A) and formic acid (0.02 M) in acetonitrile (solvent B). The gradient began initially at 0% A during 1 min, increasing linearly to 90% at 2 min; this was maintained for 2 min and then was decreased to 0% at 6 min. Finally, the last 4 min of the analysis remained at 100% B. Sample temperature was maintained at 4 °C in the autosampler prior to analysis. A sample volume of 10 μl was injected into the analytical column for compound analysis.</p>
<p>MS/MS analyses were accomplished on an Applied Biosystems MDS Sciex (Concord, Ontario, Canada) API 2000 triple quadrupole mass spectrometer equipped with an electrospray ionization (ESI) interface. ESI was performed in the positive ionization mode. A standard polypropylene glycol solution (PPG standard) was used for instrument tuning and mass calibration at unit mass resolution according to the Applied Biosystems manual. The mass spectrometer was operated with a dwell time of 200 ms. To find the optimal parameters of ion path and ion source of the studied compound, the quantitative optimization was done by direct infusion of standards using a Hamilton syringe pump (Hamilton, Reno, NV, USA). Multiple reaction monitoring (MRM) mode of the dominant product ion for each eCB was realized using the optimal conditions. The ion source parameters were as follows: ion spray voltage (IS)—5500 V, nebulizer gas (gas 1)—30 psi, turbo gas (gas 2)—10 psi, temperature of the heated nebulizer (TEM)—400 °C, and curtain gas (CUR)—25 psi. Comparison of pair ions (precursor and product ion <italic>m</italic>/<italic>z</italic> values) and LC retention times with standards served to confirm the identification of eCB in the samples investigated. Ion pairs were 348/62 for AEA, 379/287 for 2-AG, 352/66 for AEA-d<sub>4</sub>, and 384/292 for 2-AG-d<sub>5</sub>. Data acquisition and processing were accomplished using the Applied Biosystems Analyst version 1.4.2 software.</p>
</sec>
<sec id="FPar4">
<title>Calibration Curve and Quantification</title>
<p>The concentrations of eCBs in the samples were calculated using the calibration curve that was prepared on the same day and analyzed in the same analytical run. Calibration curves were constructed after analysis of the samples of brain tissues collected from naïve rats. The homogenates were spiked with AEA to the following concentrations: blank, 0.1, 1, 10, 25, 50, and 100 ng/g. For 2-AG, the following solutions were used: blank, 0.4, 1, 5, 10, 25, and 50 μg/g. AEA-d<sub>4</sub> and 2-AG-d<sub>5</sub> were used as the internal standards. The samples were analyzed according to the procedure described above (“Lipid Extraction from Brain Tissue” section).</p>
</sec>
</sec>
<sec id="Sec11">
<title>Western Blot</title>
<p>Frozen brain structures were homogenized in buffer to the homogenization (1 mM HEPES, 0.1 M DTT, 0.1 mM EGTA (pH 7.2–7.8), COMPLETE, and sterile water) using a homogenizer ball (Bioprep-24, Allsheng, China) (10 s at 10,000 rpm) and were then denatured for 2 min at 85 °C, 2 min in ice, 5 min at 85 °C, and finally 2 min in ice. For protein determination, a bicinchoninic acid assay (BCA) protein assay kit (Serva, Germany) was used. Protein samples (30 μg) were resolved by 10% SDS polyacrylamide gels and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were blocked in 3% non-fat dry milk, and separate sets of membranes were probed with rabbit anti-CB<sub>1</sub> monoclonal antibody (1:800; ab172970; Abcam, UK; Kaczocha et al. <xref ref-type="bibr" rid="CR38">2015</xref>), rabbit anti-CB<sub>2</sub> polyclonal antibody (1:500; 101550; Cayman, USA; Álvaro-Bartolomé and García-Sevilla <xref ref-type="bibr" rid="CR5">2013</xref>), goat anti-NAPE-PLD polyclonal antibody (1:200; ab95397; Abcam, UK; Kaczocha et al. <xref ref-type="bibr" rid="CR38">2015</xref>), goat anti-MAGL polyclonal antibody (1:200; ab24701; Abcam, UK), rabbit anti-DAGLα polyclonal antibody (1:200; ab81984; Abcam, UK), and mouse anti-FAAH monoclonal antibody (1:200; sc-100739; Santa Cruz Biotechnology, USA). The expressions of CB<sub>1</sub>, CB<sub>2</sub>, NAPE-PLD, FAAH, DAGLα, or MAGL were evaluated relative to that of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using rabbit anti-GAPDH polyclonal antibody (1:1500, sc-25778, Santa Cruz Biotechnology, USA). Blots were washed and incubated with donkey anti-goat secondary antibody (1:6000; 926-68074; Li-cor, USA), goat anti-rabbit secondary antibody (1:6000; 926-68071; Li-cor, USA), or goat anti-mouse (1:6000; 926-32210; Li-cor, USA) and visualized with a fluorescence detection Odyssey Clx (Li-cor, USA). Analysis was performed using Image Studio v.2.1. All data were expressed as % of control.</p>
</sec>
<sec id="Sec12">
<title>Autoradiography</title>
<p>Consecutive coronal sections (12 μm) of rat brains were cut on a cryostat microtome (Leica CM 1850, Germany) at −22 ± 2 °C and were thaw-mounted on polylysine-coated slides. Five coronal sections were mounted on a single slide and stored at −80 °C. Receptor binding assay with [<sup>3</sup>H]CP55,940 (PerkinElmer, USA; specific activity 164.5 Ci/mmol) was performed using the procedure described previously with some modifications (Adamczyk et al. <xref ref-type="bibr" rid="CR3">2012</xref>). The slices were preincubated for 2 h at 37 °C in buffer (containing 50 mM Tris–HCl with 5% bovine serum albumin; pH 7.5).</p>
<p>Total binding was measured by incubating the appropriate tissue sections with [<sup>3</sup>H]CP55,940 (2 nM) for 2 h at 37 °C in the buffer (see above). To determine the non-specific binding, parallel sections were incubated additionally in the presence of 10 μM CP55,940 (Sigma-Aldrich, USA). Following the incubation period, tissue sections were washed twice in an ice-cold (4 °C) buffer (containing 50 mM Tris–HCl with 1% bovine serum albumin; pH 7.5) for 2 h and twice in distilled water (4 °C) for 1 min, and then dried with cool air.</p>
<p>Radiolabeled, dried tissue sections were exposed to tritium-sensitive screens (3H-Fujifilm imaging plates; Bas-TR2025, Fuji Photo Film, Japan) for 10 days at 4 °C. Induced autoradiograms were read out with a reader (BAS-5000 IP Image Reader v.1.1, Fujifilm), and quantitative analysis was performed using the Fujifilm software (IMAGE GAUGE, v.4.0.). Optical densities of gray values on the film were converted into bound radioactivity with a polynomial regression curve derived from autoradiographic [<sup>3</sup>H]microscales (RPA 510, Amersham, UK) used as calibration markers. Data (fmol/mg tissue) are expressed as the mean of the percentage of the control levels ± standard error of mean (SEM).The binding signal was analyzed in several brain areas, which were identified by comparing autoradiographic images with appropriate figures from The Rat Brain Atlas of Paxinos and Watson (<xref ref-type="bibr" rid="CR59">1998</xref>) (Table <xref ref-type="table" rid="Tab1">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>The obtain regions used for quantitative analysis, chosen according to The Rat Brain Atlas (Paxinos and Watson <xref ref-type="bibr" rid="CR59">1998</xref>). The color outlines show the brain areas in which optical densities were quantified</p></caption><graphic id="MO1" xlink:href="12640_2017_9708_Tab1_HTML"></graphic></table-wrap>
</p>
</sec>
</sec>
<sec id="Sec13">
<title>Statistical Analyses</title>
<p>All data were expressed as the mean ± SEM. Statistical analyses were performed with Student’s <italic>t</italic> test. <italic>P</italic> &lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="Sec14">
<title>Results</title>
<sec id="Sec15">
<title>Behavioral Tests</title>
<sec id="Sec16">
<title>FST</title>
<p>The OBX rats displayed longer (by 30.7%) (<italic>t</italic> = 3.652; df = 14; <italic>p</italic> = 0.0026) immobility time compared with the SHAM controls (OBX rats 140.5 ± 8.0; SHAM-operated rats 107.5 ± 4.1). The WKY rats demonstrated a significantly increased (by 45.2%) (<italic>t</italic> = 2.614; df = 14; <italic>p</italic> = 0.0204) immobility time compared with the control group (WKY rats 126.9 ± 10.3; Wistar rats 87.4 ± 11.1).</p>
</sec>
<sec id="Sec17">
<title>Locomotor Activity</title>
<p>Removal of the olfactory bulbs evoked a significant enhancement of rat locomotor activity during 5-min (OBX rats 1714 ± 125; SHAM-operated rats 1132 ± 80; <italic>t</italic> = 3.929; df = 14; <italic>p</italic> = 0.015) and 30-min (OBX rats 5042 ± 330; SHAM-operated rats 3282 ± 333; <italic>t</italic> = 3.753; df = 14; <italic>p</italic> = 0.0021) trials. The locomotor activity of the WKY rats was unchanged compared with that of the control animals in the 5-min (WKY rats 1085 ± 164; Wistar rats 1025 ± 78) or 30-min (WKY rats 2883 ± 48; Wistar rats 2468 ± 209) trials.</p>
</sec>
</sec>
<sec id="Sec18">
<title>Biochemical Analyses</title>
<sec id="Sec19">
<title>eCB Tissue Content</title>
<sec id="FPar5">
<title>AEA</title>
<p>When comparing the OBX to the SHAM rats (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a), we found a significant reduction of the AEA levels in the prefrontal cortex (<italic>t</italic> = 4.487; df = 14; <italic>p</italic> = 0.0005), hippocampus (<italic>t</italic> = 5.405; df = 14; <italic>p</italic> &lt; 0.0001), and dorsal striatum (<italic>t</italic> = 3.328; df = 14; <italic>p</italic> = 0.005). At the same time, removal of the olfactory bulbs evoked a significant enhancement of the AEA levels in the nucleus accumbens (<italic>t</italic> = 7.394; df = 14; <italic>p</italic> &lt; 0.0001) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a).<fig id="Fig1"><label>Fig. 1</label><caption><p>Changes in the eCBs levels; AEA (<bold>a</bold>) and 2-AG (<bold>b</bold>) in brain structures from OBX and WKY rats. <italic>AEA</italic> anandamide, <italic>2-AG</italic> 2-arachidonoylglycerol, <italic>PFCTX</italic> prefrontal cortex, <italic>FCTX</italic> frontal cortex, <italic>HIP</italic> hippocampus, <italic>DSTR</italic> dorsal striatum, <italic>NAc</italic> nucleus accumbens, <italic>CER</italic> cerebellum, <italic>OBX</italic> bulbectomized rats, <italic>WKY</italic> Wistar Kyoto rats. All data are expressed as mean ± SEM. <italic>N</italic> = 8 rats/group. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01; ***<italic>p</italic> &lt; 0.001 vs SHAM-operated or Wistar rats</p></caption><graphic id="MO2" xlink:href="12640_2017_9708_Fig1_HTML"></graphic></fig>
</p>
<p>In the WKY rats, the levels of AEA either increased in the prefrontal cortex (<italic>t</italic> = 5.499; df = 14; <italic>p</italic> &lt; 0.0001) or decreased in the dorsal striatum (<italic>t</italic> = 2.384; df = 14; <italic>p</italic> = 0.0318), while no changes in the rest of the brain structures were observed (Fig. <xref ref-type="fig" rid="Fig1">1</xref>a).</p>
</sec>
<sec id="FPar6">
<title>2-AG</title>
<p>The 2-AG levels either increased in the prefrontal cortex (<italic>t</italic> = 3.683; df = 14; <italic>p</italic> = 0.0025) or decreased in the nucleus accumbens (<italic>t</italic> = 4.316; df = 14; <italic>p</italic> = 0.0007) in the OBX rats compared with those in the SHAM-operated controls (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b).</p>
<p>In the WKY rats, a decrease in 2-AG levels was observed in the prefrontal cortex (<italic>t</italic> = 4.715; df = 14; <italic>p</italic> = 0.0003) (Fig. <xref ref-type="fig" rid="Fig1">1</xref>b).</p>
</sec>
</sec>
<sec id="Sec20">
<title>Enzyme Protein Expression</title>
<sec id="FPar7">
<title>NAPE-PLD and FAAH</title>
<p>Removal of the olfactory bulbs induced either a decrease in NAPE-PLD protein expression in the prefrontal cortex (<italic>t</italic> = 3.001; df = 14; <italic>p</italic> = 0.0111) or an increase in the expression of this protein in the nucleus accumbens (<italic>t</italic> = 2.754; df = 14; <italic>p</italic> = 0.0175) compared with SHAM-operated rats (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a). In the WKY rats, an increase in NAPE-PLD protein expression was observed in the prefrontal cortex (<italic>t</italic> = 2.722; df = 14; <italic>p</italic> = 0.0185), and a decrease of this protein expression was shown in the nucleus accumbens (<italic>t</italic> = 2.266; df = 14; <italic>p</italic> = 0.0427) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a).<fig id="Fig2"><label>Fig. 2</label><caption><p>Changes in the expression of metabolizing enzymes of AEA synthetizing enzyme—NAPE-PLD (<bold>a</bold>) and degrading enzyme—FAAH (<bold>b</bold>) in brain structures from OBX and WKY rats. <italic>AEA</italic> anandamide, <italic>NAPE</italic>-<italic>PLD</italic> N-acyl phosphatidylethanolamine phospholipase D, <italic>FAAH</italic> fatty acid amide hydrolase, <italic>PFCTX</italic> prefrontal cortex, <italic>FCTX</italic> frontal cortex, <italic>HIP</italic> hippocampus, <italic>DSTR</italic> dorsal striatum, <italic>NAc</italic> nucleus accumbens, <italic>CER</italic> cerebellum, <italic>OBX</italic> bulbectomized rats, <italic>WKY</italic> Wistar Kyoto rats. All data are expressed as mean ± SEM. <italic>N</italic> = 8 rats/group. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01 vs SHAM-operated or Wistar rats</p></caption><graphic id="MO3" xlink:href="12640_2017_9708_Fig2_HTML"></graphic></fig>
</p>
<p>In the OBX rats, an increase of FAAH protein expression was seen in the prefrontal cortex (<italic>t</italic> = 3.058; df = 14; <italic>p</italic> = 0.0099) and hippocampus (<italic>t</italic> = 2.887; df = 14; <italic>p</italic> = 0.0137) (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b). In the WKY rats, either an increase in FAAH protein expression in the dorsal striatum (<italic>t</italic> = 3.209; df = 14; <italic>p</italic> = 0.0075) or a decrease in this protein expression in the nucleus accumbens (<italic>t</italic> = 2.255; df = 14; <italic>p</italic> = 0.0436) was noted (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b).</p>
</sec>
<sec id="FPar8">
<title>DAGLα and MAGL</title>
<p>In the OBX rats, an increase of DAGLα protein expression was noted in the prefrontal cortex (<italic>t</italic> = 2.919; df = 14; <italic>p</italic> = 0.0129) compared with that in the SHAM-operated rats, while in the WKY rats, the levels of DAGLα protein expression did not change (Fig. <xref ref-type="fig" rid="Fig3">3</xref>a).<fig id="Fig3"><label>Fig. 3</label><caption><p>Changes in the expression of metabolizing enzymes of 2-AG synthetizing enzyme—DAGLα (<bold>a</bold>) and degrading enzyme—MAGL (<bold>b</bold>) in brain structures from OBX and WKY rats. <italic>2</italic>-<italic>AG</italic> 2-arachidonoylglycerol, <italic>DAGLα</italic> diacylglycerol lipase α, <italic>MAGL</italic> monoacylglycerol lipase, <italic>PFCTX</italic> prefrontal cortex, <italic>FCTX</italic> frontal cortex, <italic>HIP</italic> hippocampus, <italic>DSTR</italic> dorsal striatum, <italic>NAc</italic> nucleus accumbens, <italic>CER</italic> cerebellum, <italic>OBX</italic> bulbectomized rats, <italic>WKY</italic> Wistar Kyoto rats. All data are expressed as mean ± SEM. <italic>N</italic> = 8 rats/group. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01; ***<italic>p</italic> &lt; 0.001 vs SHAM-operated or Wistar rats</p></caption><graphic id="MO4" xlink:href="12640_2017_9708_Fig3_HTML"></graphic></fig>
</p>
<p>Removal of the olfactory bulbs in rats evoked a reduction of MAGL protein expression in the prefrontal cortex (<italic>t</italic> = 3.876; df = 14; <italic>p</italic> = 0.0022) and frontal cortex (<italic>t</italic> = 4.994; df = 14; <italic>p</italic> = 0.0003), while in the nucleus accumbens, higher levels of MAGL protein expression were noted (<italic>t</italic> = 4.151; df = 14; <italic>p</italic> = 0.0013) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b). In the WKY rats, only a significant increase of MAGL protein expression was seen in the prefrontal cortex (<italic>t</italic> = 3.073; df = 14; <italic>p</italic> = 0.0097) (Fig. <xref ref-type="fig" rid="Fig3">3</xref>b).</p>
</sec>
</sec>
<sec id="Sec21">
<title>CB<sub>1</sub> Receptor Autoradiography</title>
<p>Differentiation of radioligand binding to the CB<sub>1</sub> receptors was dependent on the structure and was in the range of 40.40 ± 2.18 (frontal cortex layer II/III) to 384.10 ± 16.38 (substantia nigra) fmol/mg tissue in the control animals. Low values of radioligand binding (40–60 fmol/mg tissue) were seen in the motor cortex, prelimbic cortex, infralimbic cortex, frontal cortex, nucleus accumbens, amygdala, and ventral tegmental area; the mean values (between 70 and 110 fmol/mg tissue) were observed in the dorsal striatum and hippocampal areas; and the maximum binding (greater than 350 fmol/mg tissue) was observed in the substantia nigra.</p>
<p>In the OBX rats, the binding of [<sup>3</sup>H]CP55,940 either increased in the prelimbic cortex (IV–VI layers) (<italic>t</italic> = 4.031; df = 10; <italic>p</italic> = 0.0024) or decreased in the laterodorsal striatum (<italic>t</italic> = 2.6; df = 10; <italic>p</italic> = 0.0265) compared with that in the SHAM-operated rats (Table <xref ref-type="table" rid="Tab2">2</xref>). The binding of [<sup>3</sup>H]CP55,940 in the WKY rats increased in the motor cortex (I–III layers) (<italic>t</italic> = 3.399; df = 10; <italic>p</italic> = 0.0068), motor cortex (IV–VI layers) (<italic>t</italic> = 2.558; df = 10; <italic>p</italic> = 0.0285), prelimbic cortex (I–III layers) (<italic>t</italic> = 5.07; df = 10; <italic>p</italic> = 0.0005), prelimbic cortex (IV–VI layers) (<italic>t</italic> = 4.593; df = 10; <italic>p</italic> = 0.001), infralimbic cortex (<italic>t</italic> = 5.591; df = 10; <italic>p</italic> = 0.0002), frontal cortex (II–III layers) (<italic>t</italic> = 4.967; df = 10; <italic>p</italic> = 0.0006), frontal cortex (V layer) (<italic>t</italic> = 5.258; df = 10; <italic>p</italic> = 0.0004), cingulate cortex (<italic>t</italic> = 3.146; df = 10; <italic>p</italic> = 0.0104), laterodorsal striatum (<italic>t</italic> = 2.528; df = 10; <italic>p</italic> = 0.03), nucleus accumbens core (<italic>t</italic> = 3.028; df = 10; <italic>p</italic> = 0.0127), nucleus accumbens shell (<italic>t</italic> = 2.706; df = 10; <italic>p</italic> = 0.0221), amygdala (<italic>t</italic> = 2.63; df = 10; <italic>p</italic> = 0.0252), dentate gyrus of the hippocampus (<italic>t</italic> = 2.999; df = 10; <italic>p</italic> = 0.0134 and <italic>t</italic> = 4.475; df = 10; <italic>p</italic> = 0.0012), and the hippocampal CA1 (<italic>t</italic> = 2.943; df = 10; <italic>p</italic> = 0.0147) and CA3 layers (<italic>t</italic> = 3517; df = 10; <italic>p</italic> = 0,0056) compared with that in the Wistar rats (Table <xref ref-type="table" rid="Tab3">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>The binding of [<sup>3</sup>H]CP55.940 to CB<sub>1</sub> receptors in various brain areas in OBX rats</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>SHAM</th><th>OBX</th></tr></thead><tbody><tr><td>Motor cortex (I–III layers)</td><td>100.0 ± 7.97</td><td>119.9 ± 8.08</td></tr><tr><td>Motor cortex (IV–VI layers)</td><td>100.0 ± 7.64</td><td>101.3 ± 5.68</td></tr><tr><td>Prelimbic cortex (I–III layers)</td><td>100.0 ± 10.56</td><td>92.1 ± 5.11</td></tr><tr><td>Prelimbic cortex (IV–VI layers)</td><td>100.0 ± 5.08</td><td>143.9 ± 9.63**</td></tr><tr><td>Infralimbic cortex</td><td>100.0 ± 10.10</td><td>95.8 ± 5.22</td></tr><tr><td>Frontal cortex (II–III layers)</td><td>100.0 ± 8.45</td><td>109.6 ± 4.49</td></tr><tr><td>Frontal cortex (V layer)</td><td>100.0 ± 12.07</td><td>101.3 ± 5.87</td></tr><tr><td>Cingulate cortex</td><td>100.0 ± 6.28</td><td>111.8 ± 5.20</td></tr><tr><td>Laterodorsal striatum</td><td>100.0 ± 5.93</td><td>82.1 ± 3.53*</td></tr><tr><td>Mediodorsal striatum</td><td>100.0 ± 4.80</td><td>103.1 ± 6.29</td></tr><tr><td>Nucleus accumbens core</td><td>100.0 ± 10.65</td><td>100.1 ± 9.58</td></tr><tr><td>Nucleus accumbens shell</td><td>100.0 ± 13.75</td><td>89.9 ± 9.20</td></tr><tr><td>Amygdala</td><td>100.0 ± 7.98</td><td>102.7 ± 5.38</td></tr><tr><td>Dentate gyrus (hippocampus)—bregma—3.30</td><td>100.0 ± 4.15</td><td>112.6 ± 6.53</td></tr><tr><td>CA1 layer (hippocampus)—bregma—3.30</td><td>100.0 ± 6.15</td><td>93.9 ± 7.20</td></tr><tr><td>CA2 layer (hippocampus)—bregma—3.30</td><td>100.0 ± 12.66</td><td>121.3 ± 13.64</td></tr><tr><td>CA3 layer (hippocampus)—bregma—3.30</td><td>100.0 ± 4.75</td><td>101.5 ± 11.83</td></tr><tr><td>Dentate gyrus (hippocampus)–bregma—5.30</td><td>100.0 ± 6.67</td><td>95.0 ± 1.71</td></tr><tr><td>CA1 layer (hippocampus)—bregma—5.30</td><td>100.0 ± 10.85</td><td>114.1 ± 4.68</td></tr><tr><td>CA2 layer (hippocampus)—bregma—5.30</td><td>100.0 ± 8.78</td><td>112.0 ± 10.76</td></tr><tr><td>CA3 layer (hippocampus)—bregma—5.30</td><td>100.0 ± 7.15</td><td>94.3 ± 7.37</td></tr><tr><td>Ventral tegmental area</td><td>100.0 ± 4.85</td><td>97.1 ± 8.15</td></tr><tr><td>Substantia nigra</td><td>100.0 ± 4.86</td><td>99.9 ± 5.95</td></tr></tbody></table><table-wrap-foot><p>The number of animals in all examined groups was <italic>n</italic> = 6. Data are presented as the mean percent binding (±S.E.M.) relative to control (SHAM)</p><p>
<italic>OBX</italic> bulbectomized rats, <italic>SHAM</italic> SHAM-operated rats</p><p>*<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01 vs. SHAM</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab3"><label>Table 3</label><caption><p>The binding of [<sup>3</sup>H]CP55.940 to CB<sub>1</sub> receptors in various brain areas in WKY rats</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th>WISTAR</th><th>WKY</th></tr></thead><tbody><tr><td>Motor cortex (I–III layers)</td><td>100.0 ± 3.37</td><td>117.4 ± 3.86**</td></tr><tr><td>Motor cortex (IV–VI layers)</td><td>100.0 ± 5.89</td><td>115.7 ± 1.78*</td></tr><tr><td>Prelimbic cortex (I–III layers)</td><td>100.0 ± 1.66</td><td>129.9 ± 5.66***</td></tr><tr><td>Prelimbic cortex (IV–VI layers)</td><td>100.0 ± 5.73</td><td>135.2 ± 5.08***</td></tr><tr><td>Infralimbic cortex</td><td>100.0 ± 2.36</td><td>123.5 ± 3.48***</td></tr><tr><td>Frontal cortex (II–III layers)</td><td>100.0 ± 7.61</td><td>138.5 ± 1.48***</td></tr><tr><td>Frontal cortex (V layer)</td><td>100.0 ± 7.45</td><td>148.5 ± 5.43***</td></tr><tr><td>Cingulate cortex</td><td>100.0 ± 7.23</td><td>128.9 ± 5.66*</td></tr><tr><td>Laterodorsal striatum</td><td>100.0 ± 6.72</td><td>120.5 ± 4.54*</td></tr><tr><td>Mediodorsal striatum</td><td>100.0 ± 4.96</td><td>110.5 ± 3.31</td></tr><tr><td>Nucleus accumbens core</td><td>100.0 ± 7.90</td><td>129.7 ± 5.83*</td></tr><tr><td>Nucleus accumbens shell</td><td>100.0 ± 5.67</td><td>126.2 ± 7.82*</td></tr><tr><td>Amygdala</td><td>100.0 ± 8.04</td><td>123.2 ± 3.66*</td></tr><tr><td>Dentate gyrus (hippocampus)—bregma—3.30</td><td>100.0 ± 4.73</td><td>128.8 ± 8.35*</td></tr><tr><td>CA1 layer (hippocampus)—bregma—3.30</td><td>100.0 ± 4.71</td><td>113.2 ± 5.69</td></tr><tr><td>CA2 layer (hippocampus)—bregma—3.30</td><td>100.0 ± 4.54</td><td>117.0 ± 8.53</td></tr><tr><td>CA3 layer (hippocampus)—bregma—3.30</td><td>100.0 ± 5.54</td><td>103.4 ± 9.02</td></tr><tr><td>Dentate gyrus (hippocampus)—bregma—5.30</td><td>100.0 ± 6.08</td><td>129.0 ± 2.21**</td></tr><tr><td>CA1 layer (hippocampus)—bregma—5.30</td><td>100.0 ± 4.52</td><td>135.6 ± 11.24*</td></tr><tr><td>CA2 layer (hippocampus)—bregma—5.30</td><td>100.0 ± 8.55</td><td>114.7 ± 11.53</td></tr><tr><td>CA3 layer (hippocampus)—bregma—5.30</td><td>100.0 ± 5.80</td><td>123.3 ± 3.18**</td></tr><tr><td>Ventral tegmental area</td><td>100.0 ± 13.07</td><td>124.9 ± 14.88</td></tr><tr><td>Substantia nigra</td><td>100.0 ± 8.00</td><td>100.7 ± 5.72</td></tr></tbody></table><table-wrap-foot><p>The number of animals in all examined groups was <italic>n</italic> = 6. Data are presented as the mean percent binding (±S.E.M.) relative to control (Wistar)</p><p>
<italic>WKY</italic> Wistar Kyoto rats</p><p>*<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01; ***<italic>p</italic> &lt; 0.001 vs. SHAM</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec22">
<title>CB<sub>1</sub> and CB<sub>2</sub> Receptor Expression</title>
<p>Removal of the olfactory bulbs evoked a decrease in CB<sub>1</sub> receptor expression in the hippocampus (<italic>t</italic> = 2.994; df = 14; <italic>p</italic> = 0.0112), dorsal striatum (<italic>t</italic> = 3.908; df = 14; <italic>p</italic> = 0.0021), and nucleus accumbens (<italic>t</italic> = 2.648; df = 14; <italic>p</italic> = 0.0212) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a). In the WKY rats, an increase of CB<sub>1</sub> receptor expression was observed in the prefrontal cortex (<italic>t</italic> = 2.837; df = 14; <italic>p</italic> = 0.015), hippocampus (<italic>t</italic> = 3.076; df = 14; <italic>p</italic> = 0.0096), nucleus accumbens (<italic>t</italic> = 3.055; df = 14; <italic>p</italic> = 0.01), and cerebellum (<italic>t</italic> = 2.692; df = 14; <italic>p</italic> = 0.0196) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>a).<fig id="Fig4"><label>Fig. 4</label><caption><p>Changes in the expression of CB receptors CB<sub>1</sub> (<bold>a</bold>) and CB<sub>2</sub> (<bold>b</bold>) in brain structures from OBX and WKY rats. <italic>PFCTX</italic> prefrontal cortex, <italic>FCTX</italic> frontal cortex, <italic>HIP</italic> hippocampus, <italic>DSTR</italic> dorsal striatum, <italic>NAc</italic> nucleus accumbens, <italic>CER</italic> cerebellum, <italic>OBX</italic> bulbectomized rats, <italic>WKY</italic> Wistar Kyoto rats. All data are expressed as mean ± SEM. <italic>N</italic> = 8 rats/group. *<italic>p</italic> &lt; 0.05; **<italic>p</italic> &lt; 0.01 vs SHAM-operated or Wistar rats</p></caption><graphic id="MO5" xlink:href="12640_2017_9708_Fig4_HTML"></graphic></fig>
</p>
<p>In the OBX rats, a decrease of CB<sub>2</sub> receptor expression was noted in the prefrontal cortex (<italic>t</italic> = 2.857; df = 14; <italic>p</italic> = 0.0144) and hippocampus (<italic>t</italic> = 2.988; df = 14; <italic>p</italic> = 0.0113), while in the WKY rats, an increase of CB<sub>2</sub> receptor expression was present in the dorsal striatum (<italic>t</italic> = 2.396; df = 14; <italic>p</italic> = 0.0338) and cerebellum (<italic>t</italic> = 3.13; df = 14; <italic>p</italic> = 0.0087) (Fig. <xref ref-type="fig" rid="Fig4">4</xref>b).</p>
</sec>
</sec>
</sec>
<sec id="Sec23">
<title>Discussion</title>
<p>The present results show that behavioral depressive-like behavior manifested by the increased immobility time in the FST (without reduction in the locomotor activity) is paralleled by several alterations in the eCB system components. We used two models of depression utilizing completely different mechanisms for inducing a depressive phenotype. Removal of the olfactory bulbs evokes behavioral, neurochemical, and immunological changes, which are similar to alterations observed in depressive patients (Kelly et al. <xref ref-type="bibr" rid="CR39">1997</xref>; Song and Leonard <xref ref-type="bibr" rid="CR76">2005</xref>; Wang et al. <xref ref-type="bibr" rid="CR83">2010</xref>; Jastrzebska et al. <xref ref-type="bibr" rid="CR36">2015</xref>) and are reversed by chronic treatment with antidepressants (Smaga et al. <xref ref-type="bibr" rid="CR70">2012</xref>; Yuan and Slotnick <xref ref-type="bibr" rid="CR87">2014</xref>). The other animal model of depression, WKY rats, exhibits depressive-like behavior in the FST (Pare <xref ref-type="bibr" rid="CR57">1994</xref>; Armario et al. <xref ref-type="bibr" rid="CR6">1995</xref>; Lahmame and Armario <xref ref-type="bibr" rid="CR42">1996</xref>; Rittenhouse et al. <xref ref-type="bibr" rid="CR63">2002</xref>) and open field test (Pare <xref ref-type="bibr" rid="CR57">1994</xref>; Berton et al. <xref ref-type="bibr" rid="CR10">1997</xref>), together with abnormalities in some central neurochemical-dopaminergic (Jiao et al. <xref ref-type="bibr" rid="CR37">2006</xref>) and noradrenergic (Pardon et al. <xref ref-type="bibr" rid="CR56">2002</xref>) systems and hormonal dysregulation of the HPA (Solberg et al. <xref ref-type="bibr" rid="CR74">2001</xref>), as well as lower levels of brain-derived neurotrophic factor (BDNF) in the CA3 region of the hippocampus (Malkesman and Weller <xref ref-type="bibr" rid="CR47">2009</xref>).</p>
<p>In our neurochemical analysis, the OBX rats showed reduced AEA levels and increased 2-AG levels in the prefrontal cortex, while in the WKY rats, the cortical AEA levels were increased and the 2-AG contents were significantly reduced. The above data in the particular animal models of depression are partly supported by human and animal studies in which prefrontal eCB levels were either increased in alcoholic suicide victims (Vinod et al. <xref ref-type="bibr" rid="CR81">2005</xref>) and in depressed suicide victims (Hungund et al. <xref ref-type="bibr" rid="CR35">2004</xref>) or reduced following exposure to chronic unpredictable stress (CUS) (Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>). Additionally, clinical trials of untreated depressed patients demonstrated changes in serum eCB levels that parallel the changes seen in the WKY rats in our study. In fact, an increase in the AEA level (Hill et al. <xref ref-type="bibr" rid="CR30">2008c</xref>; Ho et al. <xref ref-type="bibr" rid="CR31">2012</xref>) and a decrease in the 2-AG level were observed in human female patients with major depression (Hill et al. <xref ref-type="bibr" rid="CR30">2008c</xref>). It should be noted that the WKY rats are a useful model that captures specific functional domains relevant to clinical depression and would seem most consistent with a melancholic depression profile showing severe symptoms of anxiety and depression (Willner and Belzung <xref ref-type="bibr" rid="CR85">2015</xref>). The WKY rats seem to be a genetic model of childhood depression (Malkesman and Weller <xref ref-type="bibr" rid="CR47">2009</xref>), while the OBX rats are more representative for depression in adults.</p>
<p>Changes in the levels of eCBs observed in the prefrontal cortex reflect the alteration in the expression of enzymes involved in the metabolism of these compounds. Thus, an increase in the levels of AEA in the WKY rats can result from an increase in the expression of NAPE-PLD, which is the AEA synthesizing enzyme, while a decrease in 2-AG levels in this structure may be evoked by higher expression of MAGL, a 2-AG degrading enzyme. Similar correlations were demonstrated in the OBX rats, where the reduction of AEA levels might result from the reduced synthesis by NAPE-PLD or enhanced degradation by FAAH. The increase in DAGLα expression (enzyme synthesizing 2-AG) and the decrease in MAGL expression probably caused the increase in the levels of 2-AG in the prefrontal cortex of the OBX rats. The above findings for the first time show the importance of alterations in eCB metabolizing enzymes as a potential factor inducing changes in the levels of eCBs in animal models of depression. These data complement only one report in which the FAAH activity was studied in the prefrontal cortex in rats subjected to the CUS procedure (Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>).</p>
<p>The increased AEA levels in the prefrontal cortex of the WKY rats may be involved in reduction of 5-HTergic neurotransmission and in depression-like behavior. As shown in these animals, increases in the AEA levels via activation of CB<sub>1</sub> receptors up-regulated 5-HT<sub>2A</sub> receptor activity while concurrently down-regulating 5-HT<sub>1A</sub> receptor activity (Hill et al. <xref ref-type="bibr" rid="CR27">2006</xref>). The latter neuroadaptations were observed in depressed patients (Drevets et al. <xref ref-type="bibr" rid="CR19">1999</xref>; Bhagwagar et al. <xref ref-type="bibr" rid="CR11">2004</xref>). The rise of the AEA levels may also induce emotional discomfort during depression and reinforce emotional memories of aversive stimuli (Morena et al. <xref ref-type="bibr" rid="CR55">2014</xref>). The activation of the eCB system via CB<sub>1</sub> receptors strongly modulates memory consolidation (Lafourcade et al. <xref ref-type="bibr" rid="CR41">2007</xref>). The latter changes may be further enhanced by the increased CB<sub>1</sub> receptor density in various brain areas in the WKY rats, such as in the cortical areas, which was demonstrated in our study. Furthermore, the increased expression of CB<sub>1</sub> receptors in the prefrontal cortex, seen in our study in the WKY rats and in other various animal models of depression induced by stress factors (Bortolato et al. <xref ref-type="bibr" rid="CR12">2007</xref>; Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>; McLaughlin et al. <xref ref-type="bibr" rid="CR52">2013</xref>), seems to be a common characteristic change for this type of symptom. The elevated AEA levels also decreased the concentration, metabolism, and physiological functions of 2-AG via vanilloid receptors (TRPV1) (Maccarrone et al. <xref ref-type="bibr" rid="CR46">2008</xref>; Bystrowska et al. <xref ref-type="bibr" rid="CR13">2014a</xref>), and reduced 2-AG levels were seen in the prefrontal cortex in the WKY rats in our study. To partly support the 2-AG significance in the prefrontal cortex, the antidepressant drug tranylcypromine, contrary to the WKY rats, increased the 2-AG levels in the prefrontal cortex (Hill et al. <xref ref-type="bibr" rid="CR29">2008b</xref>).</p>
<p>On the other hand, reduction of AEA levels in the prefrontal cortex in the present study following bulbectomy might be associated with alterations in monoaminergic signaling. In fact, in the OBX rats, the extracellular levels of dopamine (Prins et al. <xref ref-type="bibr" rid="CR60">2010</xref>), 5-HT (van der Stelt et al. <xref ref-type="bibr" rid="CR80">2005</xref>; Jastrzebska et al. <xref ref-type="bibr" rid="CR36">2015</xref>), and noradrenaline (Jastrzebska et al. <xref ref-type="bibr" rid="CR36">2015</xref>) were reduced in the prefrontal cortex. Homeostasis of eCB signaling may remain stable due to up-regulation of the 2-AG levels (seen in this study) or/and of the CB<sub>1</sub> receptor density in the prefrontal cortex (Rodriguez-Gaztelumendi et al. <xref ref-type="bibr" rid="CR65">2009</xref>). The increased CB<sub>1</sub> receptor density was also confirmed in our study, although this increase was demonstrated only in the prelimbic cortex (IV–VI layers) using autoradiography, while labeling of proteins with specific antibodies did not show changes in CB<sub>1</sub> receptors, and even a decrease in the CB<sub>2</sub> receptor expression in the OBX rats was observed. The reason for the differences in the levels of CB<sub>1</sub> receptors between the autoradiography and Western blot study is probably related to the internalization and trafficking of these receptors (Coutts et al. <xref ref-type="bibr" rid="CR17">2001</xref>; Leterrier et al. <xref ref-type="bibr" rid="CR45">2004</xref>). These molecular processes could explain the lack of changes in the expression of CB<sub>1</sub> receptors analyzed in homogenates of the whole structure (membrane and endogenous receptors), while changes were detected in the CB<sub>1</sub> receptor density after binding the tritiated agonist to the membrane receptors with constitutive activity during the autoradiography. Furthermore, the bulbectomy-induced increase in CB<sub>1</sub>-receptor signaling in the prefrontal cortex was reversed by chronic fluoxetine administration (Rodriguez-Gaztelumendi et al. <xref ref-type="bibr" rid="CR65">2009</xref>).</p>
<p>Our present findings also demonstrated a reduction in AEA levels in the hippocampus in the OBX rats accompanied by increased FAAH expression. AEA is metabolized primarily by FAAH, and the reduced AEA levels may impair neurogenesis in the hippocampus in the OBX rats. In fact, it was reported that hippocampal neurogenesis was reduced in depressed patients (Sheline et al. <xref ref-type="bibr" rid="CR69">1996</xref>) and in animal models of depression (Toth et al. <xref ref-type="bibr" rid="CR78">2008</xref>) probably due to AEA-mediated excitotoxic damage (Marsicano et al. <xref ref-type="bibr" rid="CR49">2003</xref>). In fact, our previous study showed that hippocampal glutamate levels are elevated in OBX rats (Jastrzebska et al. <xref ref-type="bibr" rid="CR36">2015</xref>). Antidepressant-like effects have been demonstrated after activation of the eCB system in the hippocampus following either FAAH inhibition (Bambico et al. <xref ref-type="bibr" rid="CR9">2010</xref>) or direct CB<sub>1</sub> receptor stimulation (McLaughlin et al. <xref ref-type="bibr" rid="CR51">2007</xref>). Altogether, the dampened hippocampal eCB signaling seen in our study may provoke the opposite, i.e., depression-like, effects. Our current findings are strongly supported by studies using several animal models of depression based on stress (Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>; Dubreucq et al. <xref ref-type="bibr" rid="CR20">2012</xref>). In the present study, both down-regulation of CB<sub>1</sub> and CB<sub>2</sub> receptors and a decrease in the AEA level were present in the hippocampus after bulbectomy. Administration of AEA for 5 days resulted in a significant increase in CB<sub>1</sub> receptor density in the hippocampus (Romero et al. <xref ref-type="bibr" rid="CR66">1995</xref>), so moderate activation of CB<sub>1</sub> receptor activity can result in its up-regulation in the hippocampus, while by analogy, a bulbectomy-induced decrease in AEA level provokes the decrease in CB<sub>1</sub> receptor density due to withdrawal of a trophic factor (ligand) for CB<sub>1</sub> receptor expression (Hill et al. <xref ref-type="bibr" rid="CR26">2005</xref>). Additionally, synthesis of eCBs is modulated by changes in other neurotransmitter systems (Smaga et al. <xref ref-type="bibr" rid="CR71">2014a</xref>, <xref ref-type="bibr" rid="CR72">b</xref>), so it is difficult to speculate on the exact mechanism of action of these physiological changes. However, in opposition to Vinod et al. (<xref ref-type="bibr" rid="CR82">2012</xref>), we did not detect changes in the AEA level in the hippocampus in the WKY rats. The reasons for these differences between the present and Vinod et al. (<xref ref-type="bibr" rid="CR82">2012</xref>) results are probably related to the different conditions used during eCB detection. Despite the lack of changes in the levels of endogenous ligands in this study, similar increases in the CB<sub>1</sub> receptor expression and an increase in the density of these receptors in the hippocampal dentate gyrus and CA1 and CA3 fields were noted in the WKY rats (present study; Vinod et al. <xref ref-type="bibr" rid="CR82">2012</xref>).</p>
<p>Reduction in the AEA levels was also seen in the striatum in both the OBX and WKY rats. The latter change seems to be associated with a weaker hedonic response (anhedonia), a symptom characteristic of a depressive state (Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>). Several studies have shown that attenuation of the striatal eCB signaling provoked depressive-like behavior in stress-related models (i.e., CUS and chronic mild stress (CMS)) (Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>; Reich et al. <xref ref-type="bibr" rid="CR61">2013a</xref>, <xref ref-type="bibr" rid="CR62">b</xref>; Segev et al. <xref ref-type="bibr" rid="CR68">2013</xref>) and in OBX rats (Eisenstein et al. <xref ref-type="bibr" rid="CR21">2010</xref>), while several antidepressant drugs increased the striatal AEA contents (Smaga et al. <xref ref-type="bibr" rid="CR71">2014a</xref>). The weakening of the eCB signaling in the OBX rats was supported also by a decrease in the density of CB<sub>1</sub> receptors in the laterodorsal striatum and by the lowered CB<sub>1</sub> receptor expression in the dorsal striatum. The data in the literature on rats with depressed phenotype (after CUS procedure) confirm our observations (Hill et al. <xref ref-type="bibr" rid="CR28">2008a</xref>). Interestingly, in contrast to bulbectomy-induced changes, an increase in the CB<sub>1</sub> receptor density in the laterodorsal striatum together with up-regulation of CB<sub>2</sub> receptors were observed in this structure in the WKY rats.</p>
<p>The reduced AEA levels in this structure may be either caused by the increased expression of FAAH seen in the WKY rats (but not in the OBX rats) or may be related to the decreased eCB release regulated by synaptic activity. In fact, the level of neuronal firing modulates postsynaptic eCB release from postsynaptic neurons and long-term depression (LTD) at both glutamatergic and GABAergic synapses in the striatum (Adermark et al. <xref ref-type="bibr" rid="CR4">2009</xref>). Endogenous dopamine is also involved in the generation of eCB-LTD by synaptic activity via the striatal D<sub>2</sub> receptors (Kreitzer and Malenka <xref ref-type="bibr" rid="CR40">2005</xref>), and in addition, altered dopaminergic neurotransmission has been shown to provoke anhedonia (Holmes <xref ref-type="bibr" rid="CR32">1999</xref>). Bulbectomy induces an increase in dopamine release and D<sub>1</sub> and D<sub>2</sub> receptor gene expression in the striatum (Holmes <xref ref-type="bibr" rid="CR32">1999</xref>; Masini et al. <xref ref-type="bibr" rid="CR50">2004</xref>), while alterations of this neurotransmitter evokes a decrease in the AEA release via D<sub>1</sub> receptors (Patel et al. <xref ref-type="bibr" rid="CR58">2003</xref>), which was also observed in the OBX rats in the present study. Moreover, the increased locomotor activity seen in this paper was probably related to up-regulated dopamine release in the striatum, which was also confirmed in another study (Masini et al. <xref ref-type="bibr" rid="CR50">2004</xref>).</p>
<p>The opposing regulation of AEA and 2-AG tissue contents was observed in the rat nucleus accumbens, where the AEA levels were elevated, while the 2-AG concentration decreased after bulbectomy. Interestingly, expression of the AEA synthesizing enzyme and the 2-AG degrading enzyme was increased, which can explain the changes in the eCB levels in the OBX rats. On the other hand, in the WKY rats, although there was a decrease in the expression of the enzymes synthesizing and degrading AEA, homeostasis of this mediator was not compromised, and the AEA levels did not change in the nucleus accumbens. Lack of changes in the levels of neurotransmitters, despite disturbances in metabolizing enzymes, may be associated with a local increase in the density and expression of CB<sub>1</sub> receptors in the core and shell of the nucleus accumbens in the WKY rats.</p>
<p>Changes in the eCB levels in the nucleus accumbens in the OBX rats seem to be closely related to alterations in other brain neurotransmitters. eCBs are engaged in the LTD of glutamatergic signaling in the nucleus accumbens. The glutamatergic synapses, where CB<sub>1</sub> receptors are located, modulate the firing of GABAergic neurons in the nucleus accumbens, which in turn decreases the dopaminergic neurons of the ventral tegmental area (VTA). eCBs may disinhibit dopamine cells of the VTA by reducing the excitatory transmission in the nucleus accumbens, increasing the dopamine firing rate, and provoking dopamine release in the nucleus accumbens (Robbe et al. <xref ref-type="bibr" rid="CR64">2001</xref>). In the OBX rats, it was shown that glutamatergic and GABAergic neurotransmission was dysregulated, which also led to the changes in the dopaminergic system (Song and Leonard <xref ref-type="bibr" rid="CR76">2005</xref>; Jastrzebska et al. <xref ref-type="bibr" rid="CR36">2015</xref>). Changes in the OBX rats were accompanied by reduced expression of CB<sub>1</sub> receptors in the nucleus accumbens, but this change does not seem to be related to the levels of neurotransmitters. Additionally, several papers showed that AEA administration, an FAAH inhibitor or CB<sub>1</sub> agonists evoked augmentation of dopamine concentration in the nucleus accumbens shell in rats (Hungund et al. <xref ref-type="bibr" rid="CR34">2003</xref>; Lecca et al. <xref ref-type="bibr" rid="CR43">2006</xref>; Solinas et al. <xref ref-type="bibr" rid="CR75">2006</xref>; Cadoni et al. <xref ref-type="bibr" rid="CR15">2008</xref>) as well as self-administered 2-AG stimulated dopamine release in the nucleus accumbens shell in rats (De Luca et al. <xref ref-type="bibr" rid="CR18">2014</xref>).</p>
<p>Finally, changes in the eCB system were also detected in the cerebellum only in the WKY rats, while no changes in the eCB levels and in the expression of enzymes involved in their metabolism were observed. In addition, an increase in the expression of CB<sub>1</sub> and CB<sub>2</sub> receptors was noted in the cerebellum in the WKY rats. In naïve rats, the CB<sub>1</sub> receptors are strongly expressed on basket cells located in the cerebellar cortex, where they form synapses on the cell bodies of Purkinje cells and make inhibitory synapses with Purkinje cells (Yoshida et al. <xref ref-type="bibr" rid="CR86">2002</xref>). Stimulation of the CB<sub>1</sub> receptor suppresses spontaneous inhibitory postsynaptic currents (IPSCs) and is involved in the depolarization-induced suppression of inhibition (DSI) by influencing the presynaptic inhibitory terminals (Yoshida et al. <xref ref-type="bibr" rid="CR86">2002</xref>). The strengthened eCB signaling by up-regulation of CB receptors, observed in our study, can aggravate inhibitory signals from GABA terminals in the cerebellum and induce a depression-like phenotype in the WKY rats.</p>
</sec>
<sec id="Sec24">
<title>Conclusion</title>
<p>In summary, the common change observed in both the genetic (WKY) and bulbectomy-induced models of depression entails weakness of eCB signaling (AEA) in the dorsal striatum, what can induce a characteristic symptom of depression, anhedonia. In other brain structures, neurochemical changes were different, and they seemed to be associated with the particular brain structures and the factors inducing depression. For the first time, our study showed changes in the CB<sub>2</sub> receptor expression in several brain structures in animal models of depression and the importance of alterations in eCB metabolizing enzymes as a potential factor inducing changes in eCB levels. The changes in the eCB system observed in several rat brain structures in different animal models of depression suggest a complex role of this system in the pathogenesis of depression.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>2-AG</term>
<def>
<p>2-arachidonoylglycerol</p>
</def>
</def-item>
<def-item>
<term>5-HT</term>
<def>
<p>serotonin</p>
</def>
</def-item>
<def-item>
<term>AEA</term>
<def>
<p>anandamide</p>
</def>
</def-item>
<def-item>
<term>CB</term>
<def>
<p>cannabinoid</p>
</def>
</def-item>
<def-item>
<term>DAGLα</term>
<def>
<p>diacylglycerol lipase α</p>
</def>
</def-item>
<def-item>
<term>eCB</term>
<def>
<p>endocannabinoid</p>
</def>
</def-item>
<def-item>
<term>FAAH</term>
<def>
<p>fatty acid amide hydrolase</p>
</def>
</def-item>
<def-item>
<term>LC-MS/MS</term>
<def>
<p>liquid chromatography tandem mass spectrometry</p>
</def>
</def-item>
<def-item>
<term>MAGL</term>
<def>
<p>monoacylglycerol lipase</p>
</def>
</def-item>
<def-item>
<term>NAPE-PLD</term>
<def>
<p>N-acyl phosphatidylethanolamine phospholipase D</p>
</def>
</def-item>
<def-item>
<term>OBX rats</term>
<def>
<p>bulbectomized rats</p>
</def>
</def-item>
<def-item>
<term>WKY rats</term>
<def>
<p>Wistar Kyoto rats</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgement</title>
<p>This study was supported by the research grant UMO-2012/05/B/NZ7/02589 from the National Science Centre, Kraków, Poland, and by the statutory funds from the Jagiellonian University (K/DSC/001425) and partly by the statutory funds of the Institute of Pharmacology of the Polish Academy of Sciences (Kraków). I.S. is a scholarship holder “Doctus- Malopolska scholarship program for doctoral students” (ZS.4112-51/12).</p>
</ack>
<notes notes-type="COI-statement">
<title>Compliance with Ethical Standards</title>
<sec id="FPar9">
<title>Conflict of Interest</title>
<p>The authors declare that they have no conflict of interest.</p>
</sec>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abelaira</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Reus</surname>
<given-names>GZ</given-names>
</name>
<name>
<surname>Quevedo</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Animal models as tools to study the pathophysiology of depression</article-title>
<source/>Rev Bras Psiquiatr
          <year>2013</year>
<volume>35</volume>
<issue>Suppl 2</issue>
<fpage>S112</fpage>
<lpage>S120</lpage>
<pub-id pub-id-type="doi">10.1590/1516-4446-2013-1098</pub-id>
<pub-id pub-id-type="pmid">24271223</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamczyk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Golda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McCreary</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Przegalinski</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Activation of endocannabinoid transmission induces antidepressant-like effects in rats</article-title>
<source/>J Physiol Pharmacol
          <year>2008</year>
<volume>59</volume>
<fpage>217</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="pmid">18622041</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamczyk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Faron-Gorecka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kusmider</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dziedzicka-Wasylewska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Long-lasting increase in [(3)H]CP55,940 binding to CB1 receptors following cocaine self-administration and its withdrawal in rats</article-title>
<source/>Brain Res
          <year>2012</year>
<volume>1451</volume>
<fpage>34</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2012.02.052</pub-id>
<pub-id pub-id-type="pmid">22425184</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adermark</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Talani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lovinger</surname>
<given-names>DM</given-names>
</name>
</person-group>
<article-title>Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity</article-title>
<source/>Eur J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>32</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06551.x</pub-id>
<pub-id pub-id-type="pmid">19120438</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Álvaro-Bartolomé</surname>
<given-names>M</given-names>
</name>
<name>
<surname>García-Sevilla</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Dysregulation of cannabinoid CB1 receptor and associated signaling networks in brains of cocaine addicts and cocaine-treated rodents</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>247</volume>
<fpage>294</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.05.035</pub-id>
<pub-id pub-id-type="pmid">23727505</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armario</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gavalda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marti</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Comparison of the behavioural and endocrine response to forced swimming stress in five inbred strains of rats</article-title>
<source/>Psychoneuroendocrinology
          <year>1995</year>
<volume>20</volume>
<fpage>879</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1016/0306-4530(95)00018-6</pub-id>
<pub-id pub-id-type="pmid">8834094</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aso</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ozaita</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Valdizan</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Ledent</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pazos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Valverde</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>BDNF impairment in the hippocampus is related to enhanced despair behavior in CB1 knockout mice</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>105</volume>
<fpage>565</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05149.x</pub-id>
<pub-id pub-id-type="pmid">18047561</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bambico</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Debonnel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex</article-title>
<source/>J Neurosci
          <year>2007</year>
<volume>27</volume>
<fpage>11700</fpage>
<lpage>11711</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.1636-07.2007</pub-id>
<pub-id pub-id-type="pmid">17959812</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bambico</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Cassano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dominguez-Lopez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus</article-title>
<source/>Neuropsychopharmacology
          <year>2010</year>
<volume>35</volume>
<fpage>2083</fpage>
<lpage>2100</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2010.80</pub-id>
<pub-id pub-id-type="pmid">20571484</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berton</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chaouloff</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mormde</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Behavioral reactivity to social and nonsocial stimulations: a multivariate analysis of six inbred rat strains</article-title>
<source/>Behav Genet
          <year>1997</year>
<volume>27</volume>
<fpage>155</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1023/A:1025641509809</pub-id>
<pub-id pub-id-type="pmid">9145554</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhagwagar</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rabiner</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Sargent</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Grasby</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Cowen</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635</article-title>
<source/>Mol Psychiatry
          <year>2004</year>
<volume>9</volume>
<fpage>386</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001401</pub-id>
<pub-id pub-id-type="pmid">15042104</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bortolato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mangieri</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Arguello</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Duranti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tontini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tarzia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress</article-title>
<source/>Biol Psychiatry
          <year>2007</year>
<volume>62</volume>
<fpage>1103</fpage>
<lpage>1110</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2006.12.001</pub-id>
<pub-id pub-id-type="pmid">17511970</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bystrowska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Frankowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Changes in endocannabinoid and N-acylethanolamine levels in rat brain structures following cocaine self-administration and extinction training</article-title>
<source/>Prog Neuro-Psychopharmacol Biol Psychiatry
          <year>2014</year>
<volume>50</volume>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.12.002</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bystrowska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Tyszka-Czochara</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Troubleshooting in LC-MS/MS method for determining endocannabinoid and endocannabinoid-like molecules in rat brain structures applied to assessing the brain endocannabinoid/endovanilloid system significance</article-title>
<source/>Toxicol Mech Methods
          <year>2014</year>
<volume>24</volume>
<fpage>315</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.3109/15376516.2014.898356</pub-id>
<pub-id pub-id-type="pmid">24576199</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cadoni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Di Chiara</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Behavioral sensitization to delta 9-tetrahydrocannabinol and cross-sensitization with morphine: differential changes in accumbal shell and core dopamine transmission</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>106</volume>
<fpage>1586</fpage>
<lpage>1593</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05503.x</pub-id>
<pub-id pub-id-type="pmid">18513369</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Christensen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kristensen</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Bartels</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Bliddal</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Astrup</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials</article-title>
<source/>Lancet
          <year>2007</year>
<volume>370</volume>
<fpage>1706</fpage>
<lpage>1713</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)61721-8</pub-id>
<pub-id pub-id-type="pmid">18022033</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coutts</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Anavi-Goffer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>MacEwan</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Mackie</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Irving</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons</article-title>
<source/>J Neurosci
          <year>2001</year>
<volume>21</volume>
<fpage>2425</fpage>
<lpage>2433</lpage>
<pub-id pub-id-type="pmid">11264316</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Luca</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bimpisidis</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cacciapaglia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Caboni</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Di Chiara</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Endocannabinoid 2-arachidonoylglycerol self-administration by Sprague-Dawley rats and stimulation of in vivo dopamine transmission in the nucleus accumbens shell</article-title>
<source/>Front Psychiatry
          <year>2014</year>
<volume>5</volume>
<fpage>140</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2014.00140</pub-id>
<pub-id pub-id-type="pmid">25368584</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drevets</surname>
<given-names>WC</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Kupfer</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Holt</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Greer</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gautier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mathis</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>PET imaging of serotonin 1A receptor binding in depression</article-title>
<source/>Biol Psychiatry
          <year>1999</year>
<volume>46</volume>
<fpage>1375</fpage>
<lpage>1387</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-3223(99)00189-4</pub-id>
<pub-id pub-id-type="pmid">10578452</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubreucq</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Matias</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Cardinal</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Haring</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marsicano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chaouloff</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice</article-title>
<source/>Neuropsychopharmacology
          <year>2012</year>
<volume>37</volume>
<fpage>1885</fpage>
<lpage>1900</lpage>
<pub-id pub-id-type="doi">10.1038/npp.2012.36</pub-id>
<pub-id pub-id-type="pmid">22434220</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenstein</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Clapper</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hohmann</surname>
<given-names>AG</given-names>
</name>
</person-group>
<article-title>A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy</article-title>
<source/>Pharmacol Res
          <year>2010</year>
<volume>61</volume>
<fpage>419</fpage>
<lpage>429</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2009.12.013</pub-id>
<pub-id pub-id-type="pmid">20044005</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frankowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Golda</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wydra</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gruca</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Papp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Effects of imipramine or GABA(B) receptor ligands on the immobility, swimming and climbing in the forced swim test in rats following discontinuation of cocaine self-administration</article-title>
<source/>Eur J Pharmacol
          <year>2010</year>
<volume>627</volume>
<fpage>142</fpage>
<lpage>149</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2009.10.049</pub-id>
<pub-id pub-id-type="pmid">19878670</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gobbi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bambico</surname>
<given-names>FR</given-names>
</name>
<name>
<surname>Mangieri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bortolato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Campolongo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Solinas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cassano</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Morgese</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Debonnel</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Duranti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tontini</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tarzia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Cuomo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Piomelli</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2005</year>
<volume>102</volume>
<fpage>18620</fpage>
<lpage>18625</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0509591102</pub-id>
<pub-id pub-id-type="pmid">16352709</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haring</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grieb</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Monory</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>FA</given-names>
</name>
</person-group>
<article-title>Cannabinoid CB(1) receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>65</volume>
<fpage>83</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2012.09.002</pub-id>
<pub-id pub-id-type="pmid">23000076</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2005</year>
<volume>15</volume>
<fpage>593</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2005.03.003</pub-id>
<pub-id pub-id-type="pmid">15916883</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Rademacher</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Ormerod</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress</article-title>
<source/>Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<fpage>508</fpage>
<lpage>515</lpage>
<pub-id pub-id-type="doi">10.1038/sj.npp.1300601</pub-id>
<pub-id pub-id-type="pmid">15525997</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2006</year>
<volume>9</volume>
<fpage>277</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145705005651</pub-id>
<pub-id pub-id-type="pmid">15967059</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Carrier</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>McLaughlin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Morrish</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>106</volume>
<fpage>2322</fpage>
<lpage>2336</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05567.x</pub-id>
<pub-id pub-id-type="pmid">18643796</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents</article-title>
<source/>J Neural Transm
          <year>2008</year>
<volume>115</volume>
<fpage>1673</fpage>
<lpage>1679</lpage>
<pub-id pub-id-type="doi">10.1007/s00702-008-0131-7</pub-id>
<pub-id pub-id-type="pmid">18974922</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report</article-title>
<source/>Pharmacopsychiatry
          <year>2008</year>
<volume>41</volume>
<fpage>48</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1055/s-2007-993211</pub-id>
<pub-id pub-id-type="pmid">18311684</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ho</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Serum contents of endocannabinoids are correlated with blood pressure in depressed women</article-title>
<source/>Lipids Health Dis
          <year>2012</year>
<volume>11</volume>
<fpage>32</fpage>
<pub-id pub-id-type="doi">10.1186/1476-511X-11-32</pub-id>
<pub-id pub-id-type="pmid">22373123</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>PV</given-names>
</name>
</person-group>
<article-title>Olfactory bulbectomy increases prepro-enkephalin mRNA levels in the ventral striatum in rats</article-title>
<source/>Neuropeptides
          <year>1999</year>
<volume>33</volume>
<fpage>206</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1054/npep.1999.0031</pub-id>
<pub-id pub-id-type="pmid">10657493</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cowen</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Di Simplicio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Browning</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harmer</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers</article-title>
<source/>Psychopharmacology
          <year>2009</year>
<volume>205</volume>
<fpage>85</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-009-1517-4</pub-id>
<pub-id pub-id-type="pmid">19337726</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hungund</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Szakall</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Adam</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Basavarajappa</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Vadasz</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens</article-title>
<source/>J Neurochem
          <year>2003</year>
<volume>84</volume>
<fpage>698</fpage>
<lpage>704</lpage>
<pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01576.x</pub-id>
<pub-id pub-id-type="pmid">12562514</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hungund</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Vinod</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Kassir</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Basavarajappa</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Yalamanchili</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Arango</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims</article-title>
<source/>Mol Psychiatry
          <year>2004</year>
<volume>9</volume>
<fpage>184</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001376</pub-id>
<pub-id pub-id-type="pmid">14966476</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jastrzebska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Frankowska</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Szumiec</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sadakierska-Chudy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Haduch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bystrowska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Daniel</surname>
<given-names>WA</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cocaine self-administration in Wistar-Kyoto rats: a behavioral and biochemical analysis</article-title>
<source/>Behav Brain Res
          <year>2015</year>
<volume>293</volume>
<fpage>62</fpage>
<lpage>73</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2015.06.040</pub-id>
<pub-id pub-id-type="pmid">26192911</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pare</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Tejani-Butt</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Antidepressant drug induced alterations in binding to central dopamine transporter sites in the Wistar Kyoto rat strain</article-title>
<source/>Prog Neuro-Psychopharmacol Biol Psychiatry
          <year>2006</year>
<volume>30</volume>
<fpage>30</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.06.017</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaczocha</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Glaser</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Maher</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Clavin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>J</given-names>
</name>
<name>
<surname>O'Rourke</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rebecchi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Puopolo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Owada</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Thanos</surname>
<given-names>PK</given-names>
</name>
</person-group>
<article-title>Fatty acid binding protein deletion suppresses inflammatory pain through endocannabinoid/N-acylethanolamine-dependent mechanisms</article-title>
<source/>Mol Pain
          <year>2015</year>
<volume>11</volume>
<fpage>52</fpage>
<pub-id pub-id-type="doi">10.1186/s12990-015-0056-8</pub-id>
<pub-id pub-id-type="pmid">26311517</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Wrynn</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>The olfactory bulbectomized rat as a model of depression: an update</article-title>
<source/>Pharmacol Ther
          <year>1997</year>
<volume>74</volume>
<fpage>299</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/S0163-7258(97)00004-1</pub-id>
<pub-id pub-id-type="pmid">9352586</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreitzer</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Malenka</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum</article-title>
<source/>J Neurosci
          <year>2005</year>
<volume>25</volume>
<fpage>10537</fpage>
<lpage>10545</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.2959-05.2005</pub-id>
<pub-id pub-id-type="pmid">16280591</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lafourcade</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Elezgarai</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mato</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bakiri</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Grandes</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Manzoni</surname>
<given-names>OJ</given-names>
</name>
</person-group>
<article-title>Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex</article-title>
<source/>PLoS One
          <year>2007</year>
<volume>2</volume>
<fpage>e709</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0000709</pub-id>
<pub-id pub-id-type="pmid">17684555</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahmame</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Armario</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Differential responsiveness of inbred strains of rats to antidepressants in the forced swimming test: are Wistar Kyoto rats an animal model of subsensitivity to antidepressants?</article-title>
<source/>Psychopharmacology
          <year>1996</year>
<volume>123</volume>
<fpage>191</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1007/BF02246177</pub-id>
<pub-id pub-id-type="pmid">8741943</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecca</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cacciapaglia</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Valentini</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Di Chiara</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration</article-title>
<source/>Psychopharmacology
          <year>2006</year>
<volume>188</volume>
<fpage>63</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-006-0475-3</pub-id>
<pub-id pub-id-type="pmid">16850116</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leonard</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Tuite</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat</article-title>
<source/>Int Rev Neurobiol
          <year>1981</year>
<volume>22</volume>
<fpage>251</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1016/S0074-7742(08)60295-0</pub-id>
<pub-id pub-id-type="pmid">7024168</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leterrier</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bonnard</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Carrel</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rossier</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lenkei</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Constitutive endocytic cycle of the CB1 cannabinoid receptor</article-title>
<source/>J Biol Chem
          <year>2004</year>
<volume>279</volume>
<fpage>36013</fpage>
<lpage>36021</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M403990200</pub-id>
<pub-id pub-id-type="pmid">15210689</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maccarrone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bari</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Chiara</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fezza</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Musella</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gasperi</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Prosperetti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bernardi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Finazzi-Agro</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cravatt</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Centonze</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum</article-title>
<source/>Nat Neurosci
          <year>2008</year>
<volume>11</volume>
<fpage>152</fpage>
<lpage>159</lpage>
<pub-id pub-id-type="doi">10.1038/nn2042</pub-id>
<pub-id pub-id-type="pmid">18204441</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malkesman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Weller</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Two different putative genetic animal models of childhood depression—a review</article-title>
<source/>Prog Neurobiol
          <year>2009</year>
<volume>88</volume>
<fpage>153</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1016/j.pneurobio.2009.03.003</pub-id>
<pub-id pub-id-type="pmid">19545781</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mannucci</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Navarra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pieratti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Caputi</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Calapai</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Interactions between endocannabinoid and serotonergic systems in mood disorders caused by nicotine withdrawal</article-title>
<source/>Nicotine Tob Res
          <year>2011</year>
<volume>13</volume>
<fpage>239</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1093/ntr/ntq242</pub-id>
<pub-id pub-id-type="pmid">21324836</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsicano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goodenough</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Monory</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hermann</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Eder</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cannich</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Azad</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Cascio</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Gutierrez</surname>
<given-names>SO</given-names>
</name>
<name>
<surname>van der Stelt</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lopez-Rodriguez</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Casanova</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schutz</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zieglgansberger</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Behl</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>CB1 cannabinoid receptors and on-demand defense against excitotoxicity</article-title>
<source/>Science
          <year>2003</year>
<volume>302</volume>
<fpage>84</fpage>
<lpage>88</lpage>
<pub-id pub-id-type="doi">10.1126/science.1088208</pub-id>
<pub-id pub-id-type="pmid">14526074</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masini</surname>
<given-names>CV</given-names>
</name>
<name>
<surname>Holmes</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Maki</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>GL</given-names>
</name>
</person-group>
<article-title>Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study</article-title>
<source/>Physiol Behav
          <year>2004</year>
<volume>81</volume>
<fpage>111</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1016/j.physbeh.2004.01.003</pub-id>
<pub-id pub-id-type="pmid">15059690</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLaughlin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Morrish</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Local enhancement of cannabinoid CB1 receptor signalling in the dorsal hippocampus elicits an antidepressant-like effect</article-title>
<source/>Behav Pharmacol
          <year>2007</year>
<volume>18</volume>
<fpage>431</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1097/FBP.0b013e3282ee7b44</pub-id>
<pub-id pub-id-type="pmid">17762511</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLaughlin</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Wainwright</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Galea</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Gorzalka</surname>
<given-names>BB</given-names>
</name>
</person-group>
<article-title>Upregulation of CB(1) receptor binding in the ventromedial prefrontal cortex promotes proactive stress-coping strategies following chronic stress exposure</article-title>
<source/>Behav Brain Res
          <year>2013</year>
<volume>237</volume>
<fpage>333</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2012.09.053</pub-id>
<pub-id pub-id-type="pmid">23047058</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mikics</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Aliczki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Halasz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haller</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission</article-title>
<source/>Behav Pharmacol
          <year>2009</year>
<volume>20</volume>
<fpage>265</fpage>
<lpage>272</lpage>
<pub-id pub-id-type="doi">10.1097/FBP.0b013e32832c70b1</pub-id>
<pub-id pub-id-type="pmid">19421027</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moniczewski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gawlik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Niedzielska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Krzek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Przegalinski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 1. Chemical aspects and biological sources of oxidative stress in the brain</article-title>
<source/>Pharmacol Rep
          <year>2015</year>
<volume>67</volume>
<fpage>560</fpage>
<lpage>568</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharep.2014.12.014</pub-id>
<pub-id pub-id-type="pmid">25933970</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morena</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roozendaal</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Trezza</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ratano</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Peloso</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Atsak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Trabace</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cuomo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>McGaugh</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Schelling</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Campolongo</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Endogenous cannabinoid release within prefrontal-limbic pathways affects memory consolidation of emotional training</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2014</year>
<volume>111</volume>
<fpage>18333</fpage>
<lpage>18338</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1420285111</pub-id>
<pub-id pub-id-type="pmid">25489086</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardon</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Gould</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Morilak</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Stress reactivity of the brain noradrenergic system in three rat strains differing in their neuroendocrine and behavioral responses to stress: implications for susceptibility to stress-related neuropsychiatric disorders</article-title>
<source/>Neuroscience
          <year>2002</year>
<volume>115</volume>
<fpage>229</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-4522(02)00364-0</pub-id>
<pub-id pub-id-type="pmid">12401336</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pare</surname>
<given-names>WP</given-names>
</name>
</person-group>
<article-title>Open field, learned helplessness, conditioned defensive burying, and forced-swim tests in WKY rats</article-title>
<source/>Physiol Behav
          <year>1994</year>
<volume>55</volume>
<fpage>433</fpage>
<lpage>439</lpage>
<pub-id pub-id-type="doi">10.1016/0031-9384(94)90097-3</pub-id>
<pub-id pub-id-type="pmid">8190758</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rademacher</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<article-title>Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity</article-title>
<source/>J Pharmacol Exp Ther
          <year>2003</year>
<volume>306</volume>
<fpage>880</fpage>
<lpage>888</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.103.054270</pub-id>
<pub-id pub-id-type="pmid">12808005</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Paxinos</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>C</given-names>
</name>
</person-group>
<source/>The rat brain in stereotaxic coordinates
          <year>1998</year>
<edition>4</edition>
<publisher-loc>San Diego</publisher-loc>
<publisher-name>Academic Press</publisher-name>
</element-citation>
</ref>
<ref id="CR60">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prins</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Denys</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Korte-Bouws</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Quinton</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Schreiber</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Groenink</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Korte</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats</article-title>
<source/>Eur J Pharmacol
          <year>2010</year>
<volume>633</volume>
<fpage>55</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2010.02.009</pub-id>
<pub-id pub-id-type="pmid">20153745</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reich</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Iskander</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Cannabinoid modulation of chronic mild stress-induced selective enhancement of trace fear conditioning in adolescent rats</article-title>
<source/>J Psychopharmacol
          <year>2013</year>
<volume>27</volume>
<fpage>947</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1177/0269881113499207</pub-id>
<pub-id pub-id-type="pmid">23926242</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reich</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Mihalik</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Iskander</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Seckler</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>MS</given-names>
</name>
</person-group>
<article-title>Adolescent chronic mild stress alters hippocampal CB1 receptor-mediated excitatory neurotransmission and plasticity</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>253</volume>
<fpage>444</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.08.066</pub-id>
<pub-id pub-id-type="pmid">24035826</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rittenhouse</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Lopez-Rubalcava</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stanwood</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Lucki</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Amplified behavioral and endocrine responses to forced swim stress in the Wistar-Kyoto rat</article-title>
<source/>Psychoneuroendocrinology
          <year>2002</year>
<volume>27</volume>
<fpage>303</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1016/S0306-4530(01)00052-X</pub-id>
<pub-id pub-id-type="pmid">11818168</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbe</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Alonso</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Duchamp</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bockaert</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Manzoni</surname>
<given-names>OJ</given-names>
</name>
</person-group>
<article-title>Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens</article-title>
<source/>J Neurosci
          <year>2001</year>
<volume>21</volume>
<fpage>109</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="pmid">11150326</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodriguez-Gaztelumendi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rojo</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Pazos</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Diaz</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine</article-title>
<source/>J Neurochem
          <year>2009</year>
<volume>108</volume>
<fpage>1423</fpage>
<lpage>1433</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.05898.x</pub-id>
<pub-id pub-id-type="pmid">19183263</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romero</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fernandez-Ruiz</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Cebeira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to Delta9-tetrahydrocannabinol</article-title>
<source/>Pharmacol Biochem Behav
          <year>1995</year>
<volume>51</volume>
<fpage>731</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1016/0091-3057(95)00023-P</pub-id>
<pub-id pub-id-type="pmid">7675852</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sanchis-Segura</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cline</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Marsicano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Spanagel</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Reduced sensitivity to reward in CB1 knockout mice</article-title>
<source/>Psychopharmacology
          <year>2004</year>
<volume>176</volume>
<fpage>223</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-004-1877-8</pub-id>
<pub-id pub-id-type="pmid">15083252</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<mixed-citation publication-type="other">Segev A, Rubin AS, Abush H, Richter-Levin G, and Akirav I (2013) Cannabinoid receptor activation prevents the effects of chronic mild stress on emotional learning and LTP in a rat model of depression. Neuropsychopharmacology</mixed-citation>
</ref>
<ref id="CR69">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheline</surname>
<given-names>YI</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Gado</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Csernansky</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Vannier</surname>
<given-names>MW</given-names>
</name>
</person-group>
<article-title>Hippocampal atrophy in recurrent major depression</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1996</year>
<volume>93</volume>
<fpage>3908</fpage>
<lpage>3913</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.93.9.3908</pub-id>
<pub-id pub-id-type="pmid">8632988</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pomierny</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Krzyzanowska</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pomierny-Chamiolo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Miszkiel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Niedzielska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ogorka</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: behavioral and biochemical analyses in rats</article-title>
<source/>Prog Neuro-Psychopharmacol Biol Psychiatry
          <year>2012</year>
<volume>39</volume>
<fpage>280</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2012.06.018</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<mixed-citation publication-type="other">Smaga I, Bystrowska B, Gawlinski D, Pomierny B, Stankowicz P, and Filip M (2014a) Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotox Res</mixed-citation>
</ref>
<ref id="CR72">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bystrowska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gawlinski</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Przegalinski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The endocannabinoid/endovanilloid system and depression</article-title>
<source/>Curr Neuropharmacol
          <year>2014</year>
<volume>12</volume>
<fpage>462</fpage>
<lpage>474</lpage>
<pub-id pub-id-type="doi">10.2174/1570159X12666140923205412</pub-id>
<pub-id pub-id-type="pmid">25426013</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smaga</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Niedzielska</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gawlik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moniczewski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krzek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Przegalinski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pera</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Filip</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism</article-title>
<source/>Pharmacol Rep
          <year>2015</year>
<volume>67</volume>
<fpage>569</fpage>
<lpage>580</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharep.2014.12.015</pub-id>
<pub-id pub-id-type="pmid">25933971</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solberg</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Turek</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Redei</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Altered hormone levels and circadian rhythm of activity in the WKY rat, a putative animal model of depression</article-title>
<source/>Am J Physiol Regul Integr Comp Physiol
          <year>2001</year>
<volume>281</volume>
<fpage>R786</fpage>
<lpage>R794</lpage>
<pub-id pub-id-type="pmid">11506993</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Solinas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Justinova</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Tanda</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats</article-title>
<source/>J Neurochem
          <year>2006</year>
<volume>98</volume>
<fpage>408</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2006.03880.x</pub-id>
<pub-id pub-id-type="pmid">16805835</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leonard</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>The olfactory bulbectomised rat as a model of depression</article-title>
<source/>Neurosci Biobehav Rev
          <year>2005</year>
<volume>29</volume>
<fpage>627</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2005.03.010</pub-id>
<pub-id pub-id-type="pmid">15925697</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steiner</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Marsicano</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lutz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wotjak</surname>
<given-names>CT</given-names>
</name>
</person-group>
<article-title>Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice</article-title>
<source/>Psychoneuroendocrinology
          <year>2008</year>
<volume>33</volume>
<fpage>54</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2007.09.008</pub-id>
<pub-id pub-id-type="pmid">17976922</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toth</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Gersner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wilf-Yarkoni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Raizel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dar</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Richter-Levin</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Levit</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Zangen</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Age-dependent effects of chronic stress on brain plasticity and depressive behavior</article-title>
<source/>J Neurochem
          <year>2008</year>
<volume>107</volume>
<fpage>522</fpage>
<lpage>532</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05642.x</pub-id>
<pub-id pub-id-type="pmid">18752645</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Umathe</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Manna</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>NS</given-names>
</name>
</person-group>
<article-title>Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice</article-title>
<source/>Behav Brain Res
          <year>2011</year>
<volume>223</volume>
<fpage>125</fpage>
<lpage>134</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2011.04.031</pub-id>
<pub-id pub-id-type="pmid">21549765</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Stelt</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Breuer</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Westenberg</surname>
<given-names>HG</given-names>
</name>
</person-group>
<article-title>Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study</article-title>
<source/>Biol Psychiatry
          <year>2005</year>
<volume>57</volume>
<fpage>1061</fpage>
<lpage>1067</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.12.040</pub-id>
<pub-id pub-id-type="pmid">15860347</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinod</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Arango</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kassir</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Hungund</surname>
<given-names>BL</given-names>
</name>
</person-group>
<article-title>Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims</article-title>
<source/>Biol Psychiatry
          <year>2005</year>
<volume>57</volume>
<fpage>480</fpage>
<lpage>486</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2004.11.033</pub-id>
<pub-id pub-id-type="pmid">15737662</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vinod</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Psychoyos</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hungund</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Tejani-Butt</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Dysfunction in fatty acid amide hydrolase is associated with depressive-like behavior in Wistar Kyoto rats</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<fpage>e36743</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0036743</pub-id>
<pub-id pub-id-type="pmid">22606285</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The differential effects of depression on evoked and spontaneous pain behaviors in olfactory bulbectomized rats</article-title>
<source/>Neurosci Lett
          <year>2010</year>
<volume>472</volume>
<fpage>143</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2010.01.075</pub-id>
<pub-id pub-id-type="pmid">20138969</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Will</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Aird</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Redei</surname>
<given-names>EE</given-names>
</name>
</person-group>
<article-title>Selectively bred Wistar-Kyoto rats: an animal model of depression and hyper-responsiveness to antidepressants</article-title>
<source/>Mol Psychiatry
          <year>2003</year>
<volume>8</volume>
<fpage>925</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="doi">10.1038/sj.mp.4001345</pub-id>
<pub-id pub-id-type="pmid">14593430</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Belzung</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Treatment-resistant depression: are animal models of depression fit for purpose?</article-title>
<source/>Psychopharmacology
          <year>2015</year>
<volume>232</volume>
<fpage>3473</fpage>
<lpage>3495</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-015-4034-7</pub-id>
<pub-id pub-id-type="pmid">26289353</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Maejima</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Araishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kano</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells</article-title>
<source/>J Neurosci
          <year>2002</year>
<volume>22</volume>
<fpage>1690</fpage>
<lpage>1697</lpage>
<pub-id pub-id-type="pmid">11880498</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>TF</given-names>
</name>
<name>
<surname>Slotnick</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Roles of olfactory system dysfunction in depression</article-title>
<source/>Prog Neuro-Psychopharmacol Biol Psychiatry
          <year>2014</year>
<volume>54</volume>
<fpage>26</fpage>
<lpage>30</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2014.05.013</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>